China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
PALO ALTO - Guardant Health, Inc. (NASDAQ:GH) announced Monday the expansion of its Guardant Reveal blood test to include therapy response monitoring for patients with advanced solid tumors. The company's stock, currently trading at $96.72, has surged over 216% year-to-date and sits near its 52-week high of $100.22, according to InvestingPro data.
The expanded test tracks over 20,000 epigenomic signals to measure circulating tumor DNA levels in blood, allowing physicians to predict treatment outcomes earlier than traditional imaging without requiring tissue samples. The company said results are available within seven days.
According to Guardant, the test can monitor response across therapy types, including immunotherapy and chemotherapy, and can be initiated at any point during treatment.
"By integrating therapy response monitoring into Guardant Reveal, we now have an end-to-end monitoring test built on the Smart Platform that simplifies clinical workflows," said Helmy Eltoukhy, Guardant Health Chairman and co-CEO.
The company cited recent clinical validation studies supporting the expansion. A study published in The Journal of Liquid Biopsy showed the test predicts long-term patient benefit up to 18 months earlier than standard clinical measures for chemotherapy monitoring.
Additionally, findings from the RADIOHEAD study demonstrated the test detected responses to immunotherapy up to five months earlier than standard imaging.
Guardant Health also launched a universal ordering option allowing physicians to order its portfolio of products with a single click.
The information in this article is based on a press release statement from Guardant Health.
In other recent news, Guardant Health announced an upsized offering of $350 million in 0% convertible senior notes due 2033, which was increased from the previously announced $300 million. The company also granted initial purchasers an option to purchase an additional $52.5 million in principal amount. Additionally, Guardant Health priced an upsized public offering of 3,333,333 shares of common stock at $90.00 per share, expected to generate approximately $284.4 million in net proceeds. The closing for both offerings is scheduled for November 7, 2025.
Raymond James raised its price target on Guardant Health to $115 from $61, maintaining an Outperform rating following the company's strong third-quarter results. The company reported quarterly revenues that exceeded consensus estimates by 13%, with notable growth in Guardant360 testing volumes and the Reveal product. These developments highlight significant financial maneuvers and analyst confidence in Guardant Health's performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.